News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ASLAN Pharmaceuticals Pte Ltd Reports Positive Results for Gastric Cancer Treatment



5/29/2013 8:55:48 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 28, 2013 -- Aslan Pharmaceuticals Pte reported that ASLAN001 was effective in a Phase II trial among heavily pre-treated gastric cancer patients. ASLAN001, a small-molecule pan-HER inhibitor, reduced cell proliferation and cell survival in gastric tumors that either coexpressed EGFR and HER2 or were HER2 amplified. Aslan, a Singapore based biopharma that in-licenses clinicial-stage assets, acquired global rights to the drug from Array BioPharma in 2011. More details....

Stock Symbol: (NSDQ: ARRY)



Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES